Obesity: It is body termite

Pace Hospitals

Obesity is a major health problem worldwide. Obesity also increases the risk of developing several chronic diseases such as type II diabetes, insulin resistance, coronary heart disease (responsible for heart attacks), cerebrovascular disease (responsible for strokes), high blood pressure, gout, gallstones, colon cancer, sleep apnea, and a form of liver disease called nonalcoholic fatty liver disease (NAFLD).

India the third most obese country in the world, with morbid obesity affecting 5% of the India's population

Obesity is defined as an excess amount of body fat. The normal amount of body fat (expressed as a percentage of body weight) is between 25-30% in women and 18-23% in men. Women with over 30% body fat and men with over 25% body fat are considered obese. Eighty percent of deaths related to obesity occurs in obese individuals with a BMI greater than 30.

What is non-alcoholic fatty liver disease (NAFLD)?

  •  Nonalcoholic fatty liver disease (NAFLD) refers to a wide spectrum of liver diseases ranging from the most common, fatty liver (accumulation of fat in the liver, also known as steatosis), to Nonalcoholic steatohepatitis (NASH, fat in the liver causing liver inflammation), to cirrhosis (irreversible, advanced scarring of the liver as a result of chronic inflammation of the liver). All of the stages of Nonalcoholic fatty liver disease are now believed to be due to insulin resistance, a condition closely associated with obesity. In fact, the BMI correlates with the degree of liver damage, that is, the greater the BMI the greater the liver damage.



  • The term Nonalcoholic is used because liver disease due to alcohol can show the same spectrum of liver disease as nonalcoholic fatty liver disease; however, patients with nonalcoholic fatty liver disease do not consume excessive amounts of alcohol.

Alarming statistics about non-alcoholic fatty liver disease

  • Nonalcoholic fatty liver disease is currently the most common liver disease worldwide, affecting estimated 10-24% of the world's population. That means upwards of 29 million people have nonalcoholic fatty liver disease, while 6.4 million of these persons have nonalcoholic steatohepatitis (NASH). 


  • Accumulation of fat in the liver (fatty liver) is common in all stages of nonalcoholic fatty liver disease (NAFLD). The initial stage in the spectrum of nonalcoholic fatty liver disease is fatty liver (steatosis).


  • The basic cause of nonalcoholic fatty liver disease is insulin resistance, a condition in which the effects of insulin on cells within the body are reduced. The most frequent risk factor for insulin resistance is obesity, especially abdominal obesity.


  • Fatty liver is itself quite harmless, disappears rapidly with loss of weight, and infrequently progresses to Nonalcoholic steatohepatitis, which is the next stage of nonalcoholic fatty liver disease.


  • In Nonalcoholic steatohepatitis there is accumulation of fat in the liver, but there also is inflammation (hepatitis), destruction (necrosis) of liver cells, and scarring (fibrosis) of the liver. The scarring can progress to cirrhosis, which is the last stage of nonalcoholic fatty liver disease.

 

In most patients nonalcoholic fatty liver disease causes no symptoms. Nonalcoholic fatty liver disease often is discovered when routine blood tests show slightly elevated levels of liver enzymes (ALT and AST) in the blood. Another way in which nonalcoholic fatty liver disease is discovered is when ultrasound examination of the abdomen is done for other purposes, say for looking for gallstones, and fat is found in the liver. In the late stages of non alcoholic fatty liver disease, the development of cirrhosis can lead to failure of the liver, swelling of the legs (edema), accumulation of fluid in the abdomen (ascites), bleeding from veins in the esophagus (varices), and mental confusion (hepatic encephalopathy). Patients with cirrhosis caused by Nonalcoholic fatty liver disease also may be at risk of developing liver cancer (hepatocellular carcinoma, HCC).

One common cause of liver failure (and thus a common reason for transplantation of the liver) is cryptogenic cirrhosis (cryptogenic meaning that the cause of the cirrhosis is unknown). Doctors now believe that a large number of patients with cryptogenic cirrhosis are actually patients in the late stages of nonalcoholic fatty liver disease. Doctors and public health officials project that obesity related liver diseases (cryptogenic cirrhosis and liver cancer) will become the leading cause of liver failure and liver transplantation in the not too distant future.

How are non-alcoholic fatty liver disease and non-alcoholic steatohepatitis treated? 

Losing excess weight is the cornerstone of treatment of non-alcoholic fatty liver disease. In contrast, a 10% loss of weight leads to a significant decrease in the levels of the enzymes, and the enzymes even may become normal. The decrease in enzymes occurred at the rate of 8% per 1% loss of body weight. In studies of patients undergoing stomach (gastric) reduction operations for morbid obesity, substantial weight loss is accompanied by a marked reduction in transaminases and a regression (improvement) of non alcoholic fatty liver disease.

The bottom line, however, is that the single most effective treatment for obese people with Non-alcoholic steatohepatitis is to simply lose weight through diet and exercise. Unfortunately, this is no easy task in a society dominated by a sedentary lifestyle and high-calorie, high-carbohydrate, high-fat diets. With great effort, however, weight loss is achievable. Furthermore, in view of the possible detrimental effects of fat in other liver diseases, weight loss might be added to the treatment of other liver diseases that are not primarily due to fat, such as hepatitis C. Ultimately, non alcoholic steatohepatitis probably can be largely prevented and eliminated by bariatric surgery or healthy lifestyle.


Share on

Request an appointment

Fill in the appointment form or call us instantly to book a confirmed appointment with our super specialist at 04048486868

Appointment request - health articles

Case study of a 74-year-old female with pelvic organ prolapse treated at PACE Hospitals
By Pace Hospitals April 19, 2025
Explore the Case study of a 74-year-old female with pelvic organ prolapse treated with minimally invasive laparoscopic surgery at PACE Hospitals, Hyderabad, leading to smooth recovery & relief.
 Case study of a 63-year-old man with CKD-5, tuberculosis & heart issues treated at PACE Hospitals
By Pace Hospitals April 18, 2025
Explore the complex case study of a 63-year-old man with CKD-5, tuberculosis, and heart issues. Managed with a multidisciplinary approach, highlighting the expertise and comprehensive care at PACE Hospitals.
World Immunization Week 24-30 April 2025 | Theme, Importance & History
By Pace Hospitals April 18, 2025
World Immunization Week (WIW) is a global healthcare event, typically celebrated every year in the last week of April between 24th and 30th, intending to promote vaccine usage and protect people of all ages from infectious diseases.
World Primary Immunodeficiency Week 22–29 April, Theme 2024
By Pace Hospitals April 18, 2025
World Primary Immunodeficiency (WPI) awareness week is a global healthcare event observed between the 22nd to 29th of April with the aim to raise awareness of primary immunodeficiency diseases globally.
Ankylosing spondylitis symptoms & causes | Ankylosing spondylitis treatment in India
By Pace Hospitals April 18, 2025
Ankylosing spondylitis is a type of arthritis that causes spinal inflammation. Know its symptoms, potential complications, diagnosis techniques, and treatment approaches.
Watch Dr. Seshi Janjirala from PACE Hospitals explain Acute Coronary Syndrome in this video
By Pace Hospitals April 18, 2025
Watch Dr. Seshi Vardhan Janjirala from PACE Hospitals explain Acute Coronary Syndrome (ACS), its symptoms, causes, diagnosis, and treatment options in this informative video.
PACE hospitals Podcast |Complete Urine Examination (CUE) test podcast | What is CUE Test
By Pace Hospitals April 17, 2025
Tune in to the PACE Hospitals podcast featuring Dr. A Kishore Kumar explaining the Complete Urine Examination (CUE) test covering Indications, Interpretation & Benefits.
Case study of a 44-year-old woman with incisional hernia treated at PACE Hospitals
By Pace Hospitals April 17, 2025
Case study of a 44-year-old woman from Guntur diagnosed with incisional hernia, successfully treated at PACE Hospitals by the Surgical Gastroenterology Department using open hernioplasty and mesh repair.
World Irritable Bowel Syndrome (IBS) Day  | what is IBS | IBS syndrome | IBS treatment
By Pace Hospitals April 16, 2025
Explore the significance & prevention strategies for World Irritable Bowel Syndrome Day, observed on April 19. Learn about the theme & stay informed!
Show More